Skip to main content
PROF logo

Profound Medical Corp. (PROF) Stock: Price, Forecast & Analyst Target

Profound Medical Corp. (PROF) — MoonshotScore 29/100 (Weak band), calculated Nov 18, 2026. Price $6.91 (-2.40%), as of the Nov 18, 2026 trading session; market cap $253M.

Educational signal · not a buy or sell recommendation · How to read this

$6.91 −$0.17 (-2.40%) Market Cap $253M

Profound Medical Corp. · PROF · NASDAQ

Profound Medical Corp. is a commercial-stage medical device company specializing in magnetic resonance guided ablation procedures for prostate disease, uterine fibroids, and palliative pain. Its flagship products, TULSA-PRO and Sonalleve, offer minimally invasive treatment options across Canada, Germany, the United States, and Finland.

Price as of Nov 18, 2026

Key Statistics

29 of 100

MoonshotScore v2 · Profound Medical (PROF)

Weak
Business Quality Poor (19)
Financial Safety Sound (68)
Valuation Rich (38)
Growth Durability Growing (61)
Momentum Rising (77)
Why this rating? Method, drivers & history

Bands for the MoonshotScore: Exceptional 80-100 · Strong 65-79 · Fair 45-64 · Weak below 45.

  • Business Quality — Is this a genuinely good business?
  • Financial Safety — Could this blow up on me?
  • Valuation — Am I paying a fair price?
  • Growth Durability — Is the growth real and likely to last?
  • Momentum — Is the market already moving on this?
The ten-second read ·

A strong balance sheet, but bottom-tier quality and an expensive valuation. The score also carries a risk penalty for losses on top of negative retained earnings. Business Quality: Poor; Financial Safety: Sound; Valuation: Rich; Growth Durability: Growing; Momentum: Rising.

  • quarterly revenue $5M (Q3 FY2025, quarter ended Sep 2025)
  • EPS beat 0 of the last 4 reports
  • Altman Z 6.68 · Piotroski F 4

Holding back: weak fundamentals

Helping: balance-sheet strength, positive momentum

What has the MoonshotScore done over time?

MoonshotScore snapshots recorded for PROF (52 recorded, newest six shown)
RecordedScoreBand
29Weak
29Weak
29Weak
29Weak
29Weak
29Weak

Daily score refresh is delayed. This is the last recorded calculation.

Calculation uses the most recent completed US trading session. Live price changes do not update the score immediately.

Computed · How the MoonshotScore is computed →

Price & valuation

Dates shown where recorded
MeasureValueAs of
Latest provided price$6.91
Change on the day-2.40%
52-week range$4.80 – $8.95
Market capitalisation$253M—
Shares traded on the day79.7K

Price & events

Other perspectives

Council score for Profound Medical (PROF): perspectives

Some lenses disagree with the MoonshotScore. Compare their readings below; each uses a different method.

5-Factor Breakdown

Business Quality Negative
Financial Safety Moderate
Valuation Weak
Growth Durability Moderate
Momentum Moderate

Legends Council

4 lenses, 4 current

AI simulations built from the named investors' published principles. Not affiliated with, endorsed by, or the opinion of these individuals. How these lenses are built

Griffin-style lens (simulated) Ken Griffin Unfavorable read
Englander-style lens (simulated) Izzy Englander Favorable read
Klarman-style lens (simulated) Seth Klarman Unfavorable read
Moon AI lens (model) Neutral read

Read on: Nov 20, 2026

Munger's Mindset

Balance Sheet & Valuation · historical

Financial Health Neutral
Margin of Safety Fairly Valued
Profit Margin Weak
Revenue Growth Strong
Debt/Equity Moderate
ROE Negative
Gross Margin Strong

Read on: Nov 18, 2026 · older than the 27 hours refresh window; not a current reading

How to read these bars and different assessments

Council is a separate blend of available disciplines; MoonshotScore above remains the five-pillar research rating.

Bars show each model's ordered assessment on its own scale, not a probability or a comparable investment return. The adjacent words give the assessment; more filled segments indicate a stronger model reading.

One of these lenses reads this company more favourably than the MoonshotScore does: Englander-style lens. Each lens is a separate scoring function over its own inputs, so a disagreement is a difference of method rather than a correction — the page's answer stays the MoonshotScore above.

On Nov 18, 2026, the Munger lens read the price at that time as fairly valued against its own estimate of value.

Readings on this page are from Nov 20, 2026, except a card that shows its own read date.

1 · What is it?

What is Profound Medical (PROF), and what does it report?

Short answer

A current FMP business description is unavailable; the listing and provider classification below are the available identity facts. Profound Medical Corp. (PROF) is listed on NASDAQ. It employs 162 people and is led by Arun Swarup Menawat. In Q3 FY2025 it reported revenue of $5M and net income of -$8M. The market values it at $253M.

2 · Latest results

What do the latest results show for Profound Medical (PROF)?

Short answer · as of

The most recent reported quarter, Q3 FY2025, carried revenue of $5M. Against analyst estimates the company has EPS beat 0 of the last 4 reports.

Quarterly income statement — 4 quarters
Revenue, net income and earnings per share by quarter
PeriodRevenueNet incomeEPS
Q3 FY2025$5M-$8M-$0.26 (diluted)
Q4 FY2025$6M-$8M-$0.27 (diluted)
Q1 FY2026$5M-$7M-$0.19 (diluted)
Q2 FY2026$2M-$10M-$0.26 (diluted)
3 · Financial strengths and risks

What are the financial strengths and risks for Profound Medical (PROF)?

Short answer · as of

The MoonshotScore pillars rate balance-sheet strength, positive momentum as strengths. What is holding it back is weak fundamentals. The distress and quality screens read Altman Z 6.68 · Piotroski F 4. Trailing ratios: ROE -59.2% · ROA -55.5% · current ratio 4.54 · earnings yield -12.1% · free-cash-flow yield -11.7%.

Data-derived red flags

  • Negative return on equity (-59.2%) — the business is not currently generating profit on shareholder capital.
  • Inconsistent delivery — missed Wall Street EPS estimates in 0 of the last 4 reported quarters.
4 · What to check next?

What should you watch next at Profound Medical (PROF)?

Short answer · as of

Current published price targets run low $11.00 · high $11.00 · consensus $11.00 · median $11.00 against a quoted price of $6.91 (as of Nov 18, 2026).

What the records here don't tell us

  • No forward revenue or earnings estimate is on file.
  • The next earnings date is not yet scheduled in the calendar we read.
  • The newest quarter held here (Q3 FY2025) was filed Nov 13, 2025 — 11 months ago.

Checked against the records this page reads, on the dates shown above.

5 · Peer comparison

How does Profound Medical compare with its peers?

Short answer

Profound Medical's score ranks 13th of 13 in the bounded comparison shown, against 12 same-model peers. These are company scores, not expected investment returns. The set lists named competitors first, then companies in the same data-provider industry classification closest in market value; that classification is the provider's, not our judgment of business similarity.

Peer set — price, market value and MoonshotScore
CompanyPriceMarket valueScore
Delcath Systems, Inc. (DCTH) Same industry, near in market value$19.70 Nov 18, 2026$685M94 5-pillar Nov 18, 2026
Tactile Systems Technology, Inc. (TCMD) Same industry, near in market value$26.42 Nov 18, 2026$592M90 5-pillar Nov 18, 2026
Viemed Healthcare, Inc. (VMD) Same industry, near in market value$8.78 Nov 18, 2026$333M88 5-pillar Nov 18, 2026
Electromed, Inc. (ELMD) Same industry, near in market value$23.40 Nov 18, 2026$191M87 5-pillar Nov 18, 2026
BrainsWay Ltd. (BWAY) Same industry, near in market value$8.98 Nov 18, 2026$361M87 5-pillar Nov 18, 2026
Bioventus Inc. (BVS) Same industry, near in market value$10.62 Nov 18, 2026$727M79 5-pillar Nov 18, 2026
Anika Therapeutics, Inc. (ANIK) Same industry, near in market value$13.62 Nov 18, 2026$182M71 5-pillar Nov 18, 2026
Solana Company (HSDT) Same industry, near in market value$1.63 Nov 18, 2026$103M43 5-pillar Nov 18, 2026
Owlet, Inc. (OWLT) Same industry, near in market value$3.67 Nov 18, 2026$110M41 5-pillar Nov 18, 2026
Inogen, Inc. (INGN) Same industry, near in market value$5.57 Nov 18, 2026$145M37 5-pillar Nov 18, 2026
Orthofix Medical Inc. (OFIX) Same industry, near in market value$6.61 Nov 18, 2026$269M36 5-pillar Nov 18, 2026
908 Devices Inc. (MASS) Same industry, near in market value$9.52 Nov 18, 2026$396M35 5-pillar Nov 18, 2026
Profound Medical (PROF) — this page$6.91$253M29

Only 5-pillar scores are ranked together. Other models are not directly comparable. Price and score dates are shown separately; market-value dates are unavailable.

The records behind this page

Analyst targets & estimates

What analysts have on file

Price target, low to high
$11.00 – $11.00
Consensus target
$11.00
Median target
$11.00

Consensus record · Captured .

Measured against a quoted price of $6.91 (as of Nov 18, 2026).

Insider activity

Form 4 records via FMP · Most recent available transactions

Transactions
2
Identified insiders
1
Purchases
2
Sales
0
Other transactions
0

Purchases and sales use the reported transaction category. Other transactions include awards, exercises, gifts, withholding and unclassified activity; an acquisition or disposition alone is not a purchase or sale. These records do not establish intent.

Who holds the shares?

Institutional ownership reported through 13F filings.

Tracked investors

Which of the 16 named investors we follow held PROF in their latest 13F filing, and what they did against the filing before it.

None of the 16 tracked investors reported PROF in their latest 13F filing.

See all tracked investor portfolios

How to read these figures

These filings arrive after the quarter ends. Names appear as the provider lists them, not as a verified ranking, and without filing dates. Related managers can appear separately, so their shares are not added together. Tracked investors: each fund's own latest 13F, so funds that have not filed the newest quarter yet show their previous one; weight is the share of the fund's reported 13F value.

What has been published about Profound Medical (PROF)?

Read these with our analysis →

What Investors Ask About Profound Medical (PROF)

These answers are editorial: 1 of these 9 answers is drawn from the PROF research dossier (written Jun 14, 2026 by gemini-2.5-flash); the other 8 are question templates that restate figures shown above. Figures in this section are not part of the source register.

What does the MoonshotScore mean for PROF?

PROF carries the MoonshotScore stated above — the Weak band. This is an educational research signal, not a buy or sell recommendation. The number comes from the five-pillar engine (business quality, financial safety, valuation, growth durability, momentum), re-ranked daily against sector peers.

Is PROF a good stock to buy?

Stock Expert AI does not rate PROF buy, sell or hold. Profound Medical Corp. carries a MoonshotScore, in the Weak band, a research rating against its peers rather than a forecast. Whether it fits is your call: check what it sells, whether it earns and what the price assumes. This is educational content, not investment advice.

What is the PROF stock price today?

The last price recorded for Profound Medical Corp. (PROF), with its trading session and source, is listed under Price & valuation on this page. It is a provider snapshot, not a live exchange feed, so check a brokerage quote before you trade.

What is the PROF price target?

The analyst consensus price target for Profound Medical Corp. (PROF), with its range and the date it was captured from FMP, is listed under Analyst targets & estimates on this page. Targets are analyst opinions and change often; they are not a Stock Expert AI forecast.

What is the market potential for Profound Medical Corp.'s TULSA-PRO system?

The TULSA-PRO system addresses a substantial and growing market for prostate disease treatment, including both benign prostatic hyperplasia (BPH) and localized prostate cancer. Prostate conditions affect millions of men globally, with an increasing prevalence due to an aging population.

What are the key factors to evaluate for PROF?

Profound Medical Corp. (PROF) holds a MoonshotScore in the low range. To weigh it, read the analyst view under Analyst targets & estimates on this page. With an aging global male population, the incidence of prostate conditions is substantial. Not financial advice.

How frequently does PROF data refresh on this page?

PROF's price is the last quote we recorded, from the Nov 18, 2026 trading session. Pages are served from a cache, so the copy you are reading can lag that quote. The quote is a provider snapshot, not an exchange feed. Fundamentals follow quarterly filings. V2 is recalculated from the most recent completed US trading session; the score's own date shows its last successful run.

What has driven PROF's recent stock price performance?

Profound Medical Corp. (PROF) moves on earnings results, analyst revisions, sector rotation, and market sentiment. Notable catalyst: Proprietary and advanced magnetic resonance guided ablation technology (TULSA-PRO and Sonalleve). See the News tab for the latest drivers. Past performance does not predict future results.

Should investors consider PROF overvalued or undervalued right now?

Profound Medical Corp. (PROF) has no trailing P/E available here, so lean on price-to-sales and cash flow in the Financials tab. Its analyst consensus target is listed under Analyst targets & estimates on this page. Compare P/E, P/S, and EV/EBITDA against sector peers for a full view.

Machine-generated analysis by Stock Expert AI — model gemini-2.5-flash, generated Jun 14, 2026. Editorial oversight is systemic, not page-by-page. Editorially accountable: Sedat ANAK, Founder and Editor-in-Chief.

Sources: the source register lists the 20 figures on this page — 13 from Financial Modeling Prep (FMP), 6 with no recorded source and 1 from Stock Expert AI's own score and rank. Its rows (value as shown, as-of date, tier and source link) are in the Markdown version of this page.

Publication details and research sources
Published
Research standards
Methodology · Editorial policy · Corrections
Data Sources & Methodology
Figures come from Financial Modeling Prep (FMP). If FMP has no figure for a ticker, a price or fundamental may come from a Yahoo Finance fallback, or a price from an Alpaca fallback. SEC EDGAR is used only for filing links and company identity details (legal name, address), never for figures. AI analysis by Stock Expert AI proprietary algorithms. Technical indicators via industry-standard calculations. Last updated: .
Data Provenance
Sources: Financial Modeling Prep (FMP) — Primary · Yahoo Finance — Fallback · Alpaca — Tertiary
Last fetched:
Cache TTL: Quote 5min · Profile 7d · Financials 7d · Insider 48h
How we use AI: Numbers are pulled directly from FMP & Yahoo Finance — our AI writes the analysis, it never edits the figures.